Dehydroepiandrosterone 100 and 400 mg ( DrugBank: Dehydroepiandrosterone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 1 |
113. Muscular dystrophy
Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00167609 (ClinicalTrials.gov) | November 2004 | 10/9/2005 | Efficacy and Safety of DHEA for Myotonic Dystrophy | Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy | Myotonic Dystrophy | Drug: dehydroepiandrosterone 100 and 400 mg | University of Versailles | Association Française contre les Myopathies (AFM), Paris;AP-HP | Completed | 18 Years | 70 Years | Both | 75 | Phase 2/Phase 3 | France |